Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Finished Goods (2023 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Finished Goods for 3 consecutive years, with $16.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Finished Goods rose 68.7% year-over-year to $16.2 million, compared with a TTM value of $16.2 million through Dec 2025, up 68.7%, and an annual FY2025 reading of $16.2 million, up 68.7% over the prior year.
  • Finished Goods was $16.2 million for Q4 2025 at Catalyst Pharmaceuticals, up from $11.3 million in the prior quarter.
  • Across five years, Finished Goods topped out at $16.2 million in Q4 2025 and bottomed at $8.1 million in Q1 2025.
  • Average Finished Goods over 3 years is $10.0 million, with a median of $9.2 million recorded in 2023.
  • Peak annual rise in Finished Goods hit 68.7% in 2025, while the deepest fall reached 3.29% in 2025.
  • Year by year, Finished Goods stood at $9.2 million in 2023, then rose by 4.55% to $9.6 million in 2024, then surged by 68.7% to $16.2 million in 2025.
  • Business Quant data shows Finished Goods for CPRX at $16.2 million in Q4 2025, $11.3 million in Q3 2025, and $8.1 million in Q2 2025.